肠道微生态干预制剂治疗幽门螺杆菌相关慢性胃炎的临床价值研究

Correlation Study between Intestinal Microbiota Intervention Agents and Helicobacter Pylori Associated Chronic Gastritis

目的研究肠道微生态干预制剂治疗幽门螺杆菌(Helicobacter pylori)相关慢性胃炎的临床价值。方法选择2022年1-10月本院收治的Hp相关慢性胃炎患者94例为研究对象,随机分为两组,其中对照组采取标准四联方案,而观察组在此基础上,再联合肠道微生态干预制剂进行治疗,比较两组治疗效果。结果干预前,两组症状评分比较无差异(P>0.05);干预后,观察组的食欲差、恶心呕吐、胃灼热感以及上腹部不适等各项评分均低于对照组(P<0.05);与对照组比较,观察组治疗有效率高,组间对比差异明显(P<0.05);观察组Hp根治率比对照组高(P<0.05);同时,两组外周血T淋巴细胞亚群水平比较有统计学意义(P<0.05)。结论临床上运用肠道微生态干预制剂对Hp相关慢性胃炎患者进行治疗,能够提高Hp根除率,调节细胞免疫状态,减轻症状,从而提高治疗效果。

Objective To investigate relationship between Helicobacter pylori(Hp)related chronic gastritis and intestinal microbiota intervention agents.Methods The paper chose 94 patients with Hp related chronic gastritis admitted to our hospital from January to October 2022 as study objects,and divided them into two groups randomly.Control group was treated with standard quadruple scheme,while observation group was combined with intestinal microbiota intervention preparations.Treatment effect between two groups was compared.Results Before intervention,there was no difference in symptom scores between two groups(P>0.05).After intervention,scores of poor appetite,nausea and vomiting,heartburn and epigastrium discomfort in observation group were lower than control group(P<0.05).Observation group had higher effective rate of treatment than control group,there was significant difference between the groups(P<0.05).Hp radical cure rate in observation group was higher than control group(P<0.05).Meanwhile,there was statistically significant difference in levels of peripheral blood T lymphocyte subsets between two groups(P<0.05).Conclusion Intestinal microbiota intervention agents can increase eradication rate of Hp,regulate cellular immune status,alleviate symptoms and improve treatment effect in clinical treatment of Hp related chronic gastritis patients.